medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2021, Number 3

<< Back Next >>

Rev Mex Urol 2021; 81 (3)

Oncologic and functional results of open radical prostatectomy as treatment of prostate cancer in a cohort of 1420 patients in Mexico City

Torres-García A, Alvarado-Larraguivel R, González-Téllez CO, Paredes-Hernández MA

Language: Spanish
References: 22
Page: 1-15
PDF size: 566.81 Kb.


ABSTRACT

Open radical prostatectomy, since the beginning of the last century has been the gold standard in the localized prostate cancer treatment, and the platform from which minimally invasive procedures such as laparoscopy and robot-assisted surgery have reproduced its results.
Objective: To evaluate the oncological outcomes and functional results of open radical prostatectomy in a cohort of 1420 patients in Mexico City.
Material and methods: A retrospective cohort study of 1420 cases of patients with prostate cancer undergoing radical surgery for a single surgeon (ATG) in private care hospitals.
Results: The median surveillance was 132 months (range 1 to 180 months). Cancer- specific survival was 95% (95% CI 96 to 9), 90% (95% CI 9 to 9), 7% (95% CI 6 to 9), % (95% CI to 6) and 0% (95% CI 79), at 5, 10 and 15 years respectively. The time free of biochemical progression decreased with greater the risk group, Gleason grade and extraprostatic extension at surgery time.
Conclusion: Radical prostatectomy is up to now a procedure that offers cancer-specific survival as well as survival free of biochemical progression adequate to achieve adequate control of prostate neoplasia.


REFERENCES

  1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ ijc.25516

  2. Malvezzi M, Bosetti C, Chatenoud L, Rodríguez T, Levi F, Negri E, et al. Trends in cancer mortality in Mexico, 1970-1999. Ann Oncol. 2004;15(11):1712–8. doi: 10.1093/annonc/ mdh424

  3. Dirección General de Información en Salud. Defunciones (Mortalidad) Cubos dinámicos. México; 2020. http://www.dgis.salud.gob.mx/ contenidos/basesdedatos/bdc_defunciones_ gobmx.html

  4. Sánchez-Barriga JJ. Tendencias de mortalidad y años potenciales de vida perdidos por cáncer de próstata en los 32 estados y en las 7 regiones socioeconómicas de México en el periodo 2000- 2010. Gac Med Mex. 2013;149(5):576–85.

  5. Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. J Urol. 2002;168(3):914–21. doi: 10.1016/s0022- 5347(05)64542-9

  6. Millin T. Retropubic prostatectomy; a new extravesical technique; report of 20 cases. Lancet. 1945;2(6380):693–6. doi: 10.1016/ s0140-6736(45)91030-0

  7. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4(5):473–85. doi: 10.1002/pros.2990040506

  8. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165(4):1146–51.

  9. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30. doi: 10.1016/ s0090-4295(97)00238-0

  10. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96. doi: 10.1097/ SLA.0b013e3181b13ca2

  11. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012;188(6):2219– 24. doi: 10.1016/j.juro.2012.08.028

  12. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27(26):4300–5. doi: 10.1200/ JCO.2008.18.2501

  13. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152(5 Pt 2):1850–7. doi: 10.1016/ s0022-5347(17)32399-6

  14. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001;166(5):1692–7.

  15. Kotb AF, Elabbady AA. Prognostic factors for the development of biochemical recurrence after radical prostatectomy. Prostate Cancer. 2011; 2011:485189. doi: 10.1155/2011/485189

  16. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D’amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179(4):1354–60; discussion 1360-1361. doi: 10.1016/j.juro.2007.11.061

  17. Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Longterm outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology. 2012;79(3):626–31. doi: 10.1016/j. urology.2011.09.051

  18. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008 Mar 15;112(6):1254–63. doi: 10.1002/cncr.23293

  19. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167(2 Pt 1):528–34. doi: 10.1097/00005392-200202000-00018

  20. Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4. doi: 10.1097/01.ju.0000134888.22332.bb

  21. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555–65. doi: 10.1016/s0094- 0143(05)70163-4

  22. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–75. doi: 10.1016/j.juro.2010.10.057




2020     |     www.medigraphic.com